HIV-1-infection
312
36
63
155
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
51 trials with published results (16%)
Research Maturity
155 completed trials (50% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.1%
16 terminated out of 312 trials
90.6%
+4.1% vs benchmark
25%
77 trials in Phase 3/4
33%
51 of 155 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 155 completed trials
Clinical Trials (312)
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa
Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
SYV: A Mental Health Intervention to Improve HIV Outcomes in Tanzanian Youth
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIV
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV
Thetha Nami Ngithethe Nawe ("Let's Talk"): Step Wedge cRCT of Peer Led Community PrEP and SRH for Youth in South Africa
SkIn, Muscle and Bone Aging Determinants in HIV Infected-patients.
IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study
Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments